These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 22506490)

  • 1. Antipsychotic polypharmacy: never say never, but never say always.
    Stahl SM
    Acta Psychiatr Scand; 2012 May; 125(5):349-51. PubMed ID: 22506490
    [No Abstract]   [Full Text] [Related]  

  • 2. Emerging guidelines for the use of antipsychotic polypharmacy.
    Stahl SM
    Rev Psiquiatr Salud Ment; 2013; 6(3):97-100. PubMed ID: 23485567
    [No Abstract]   [Full Text] [Related]  

  • 3. Antipsychotic polypharmacy: are two ever better than one?
    Goff DC; Dixon L
    Am J Psychiatry; 2011 Jul; 168(7):667-9. PubMed ID: 21724670
    [No Abstract]   [Full Text] [Related]  

  • 4. A clinical case series of switching from antipsychotic polypharmacy to monotherapy with a second-generation agent on patients with chronic schizophrenia.
    Suzuki T; Uchida H; Watanabe K; Yagi G; Kashima H
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):361-9. PubMed ID: 14751434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and social determinants of antipsychotic polypharmacy for Chinese patients with schizophrenia.
    Xiang YT; Weng YZ; Leung CM; Tang WK; Ungvari GS
    Pharmacopsychiatry; 2007 Mar; 40(2):47-52. PubMed ID: 17447172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine D2 receptors as treatment targets in schizophrenia.
    Seeman P
    Clin Schizophr Relat Psychoses; 2010 Apr; 4(1):56-73. PubMed ID: 20643630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monotherapy versus polypharmacy for hospitalized psychiatric patients.
    Strous RD; Lerner V
    Am J Psychiatry; 2005 Mar; 162(3):631-2; author reply 632-3. PubMed ID: 15741496
    [No Abstract]   [Full Text] [Related]  

  • 8. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.
    Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R; Valuck RJ
    Clin Ther; 2007 Jan; 29(1):183-95. PubMed ID: 17379060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Polypharmacy in the treatment of schizophrenia].
    Messer T; Tiltscher C; Schmauss M
    Fortschr Neurol Psychiatr; 2006 Jul; 74(7):377-91. PubMed ID: 16804806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Schizophrenia.
    Freedman R
    N Engl J Med; 2003 Oct; 349(18):1738-49. PubMed ID: 14585943
    [No Abstract]   [Full Text] [Related]  

  • 11. Focus on polypharmacy in schizophrenia: does anyone truly benefit?
    Goff DC; Freudenreich O
    Int J Neuropsychopharmacol; 2004 Jun; 7(2):109-11. PubMed ID: 15137932
    [No Abstract]   [Full Text] [Related]  

  • 12. Amisulpride monotherapy in a patient with clozapine-resistant schizophrenia.
    Pehlivanidis A; Spyropoulou AC; Tourkantonis A; Papadimitriou GN
    Clin Neuropharmacol; 2010 May; 33(3):168. PubMed ID: 20502137
    [No Abstract]   [Full Text] [Related]  

  • 13. Antipsychotic polypharmacy in patients with schizophrenia in a brief hospitalization unit.
    Lerma-Carrillo I; de Pablo Brühlmann S; del Pozo ML; Pascual-Pinazo F; Molina JD; Baca-García E
    Clin Neuropharmacol; 2008; 31(6):319-32. PubMed ID: 19050409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine2 receptor occupancy and the action of clozapine: does it make a difference to add a neuroleptic?
    Meltzer HY
    Biol Psychiatry; 1999 Jul; 46(1):144-9. PubMed ID: 10394487
    [No Abstract]   [Full Text] [Related]  

  • 15. Antipsychotic polypharmacy: do benefits justify the risks?
    Tapp AM; Wood AE; Kilzieh N; Kennedy A; Raskind MA
    Ann Pharmacother; 2005 Oct; 39(10):1759-60. PubMed ID: 16144885
    [No Abstract]   [Full Text] [Related]  

  • 16. [Neurobiology in the neuropharmacology of antipsychotic drugs].
    Tassin JP
    Encephale; 2006 Jan; 32 Pt 2():S6-7. PubMed ID: 16800077
    [No Abstract]   [Full Text] [Related]  

  • 17. Antipsychotic polypharmacy in inpatients with schizophrenia in Asia (2001-2009).
    Xiang YT; Wang CY; Si TM; Lee EH; He YL; Ungvari GS; Chiu HF; Yang SY; Chong MY; Tan CH; Kua EH; Fujii S; Sim K; Yong KH; Trivedi JK; Chung EK; Udomratn P; Chee KY; Sartorius N; Shinfuku N
    Pharmacopsychiatry; 2012 Jan; 45(1):7-12. PubMed ID: 21989602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression.
    Gründer G
    Curr Opin Investig Drugs; 2010 Jul; 11(7):823-32. PubMed ID: 20571978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder.
    Elie D; Poirier M; Chianetta J; Durand M; Grégoire C; Grignon S
    J Psychopharmacol; 2010 Jul; 24(7):1037-44. PubMed ID: 19164494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.